TAK-220是一种新型小分子CCR5拮抗剂，在体外与其他抗逆转录病毒药物具有良好的抗人类免疫缺陷病毒相互作用。
TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.
作者信息
Tremblay Cécile L, Giguel Françoise, Guan Yongbiao, Chou Ting-Chao, Takashima Katsunori, Hirsch Martin S
机构信息
Massachusetts General Hospital, 65 Landsdowne St., Room 419, Cambridge, MA 02139, USA.
出版信息
Antimicrob Agents Chemother. 2005 Aug;49(8):3483-5. doi: 10.1128/AAC.49.8.3483-3485.2005.
Abstract
TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.
摘要
TAK-220是一种CCR5拮抗剂，属于新型抗人类免疫缺陷病毒1型（抗HIV-1）进入抑制剂。我们在体外评估了TAK-220与各种抗逆转录病毒药物之间的抗HIV-1相互作用。在90%和95%抑制浓度下，与所有药物均观察到协同作用。观察到的良好药物相互作用表明有必要进行进一步的临床评估。
相似文献
1
TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.TAK-220是一种新型小分子CCR5拮抗剂，在体外与其他抗逆转录病毒药物具有良好的抗人类免疫缺陷病毒相互作用。
Antimicrob Agents Chemother. 2005 Aug;49(8):3483-5. doi: 10.1128/AAC.49.8.3483-3485.2005.
2
Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.口服生物可利用的小分子CCR5拮抗剂TAK-220对人免疫缺陷病毒1型复制具有高效抑制作用。
Antimicrob Agents Chemother. 2005 Aug;49(8):3474-82. doi: 10.1128/AAC.49.8.3474-3482.2005.
3
TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.TAK-652在体外可抑制CCR5介导的1型人类免疫缺陷病毒感染，且在人体中具有良好的药代动力学特性。
Antimicrob Agents Chemother. 2005 Nov;49(11):4584-91. doi: 10.1128/AAC.49.11.4584-4591.2005.
4
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.基于螺二酮哌嗪的CCR5抑制剂，其保留CC趋化因子/CCR5相互作用并在体外对R5型人类免疫缺陷病毒1型发挥强效活性。
J Virol. 2004 Aug;78(16):8654-62. doi: 10.1128/JVI.78.16.8654-8662.2004.
5
6
Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.小分子CCR5拮抗剂对1型人类免疫缺陷病毒包膜介导的膜融合及病毒复制的抑制作用
Antimicrob Agents Chemother. 2001 Dec;45(12):3538-43. doi: 10.1128/AAC.45.12.3538-3543.2001.
7
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.对小分子CCR5拮抗剂TAK-652耐药的1型人类免疫缺陷病毒的分离与鉴定
Antimicrob Agents Chemother. 2007 Feb;51(2):707-15. doi: 10.1128/AAC.01079-06. Epub 2006 Nov 20.
8
Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.CCR5拮抗剂AK602/ONO4128/GW873140在新型人外周血单个核细胞非肥胖糖尿病-重症联合免疫缺陷、白细胞介素-2受体γ链敲除的艾滋病小鼠模型中对R5型人类免疫缺陷病毒1型具有强效抑制作用。
J Virol. 2005 Feb;79(4):2087-96. doi: 10.1128/JVI.79.4.2087-2096.2005.
9
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.维克维若克（SCH 417690）的发现与特性研究，一种对1型人类免疫缺陷病毒具有强效活性的CCR5拮抗剂。
Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9. doi: 10.1128/AAC.49.12.4911-4919.2005.
引用本文的文献
1
Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses.抗病毒药物的现状与策略：第一部分：DNA病毒和逆转录病毒
Adv Antivir Drug Des. 2007;5:1-58. doi: 10.1016/S1075-8593(06)05001-5. Epub 2007 Sep 2.
2
Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.AMD11070（一种口服的CXCR4进入抑制剂）的抗逆转录病毒活性：美国国立卫生研究院/美国国立过敏与传染病研究所艾滋病临床试验组A5210方案的结果
AIDS Res Hum Retroviruses. 2019 Aug;35(8):691-697. doi: 10.1089/AID.2018.0256. Epub 2019 Jun 18.
3
Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus-Cell Interface.双功能嵌合体，协调靶向病毒-细胞界面的人类免疫缺陷病毒 1 包膜 gp120 和宿主细胞 CCR5 共受体。
J Med Chem. 2018 Jun 14;61(11):5020-5033. doi: 10.1021/acs.jmedchem.8b00477. Epub 2018 Jun 1.
4
Targeting CCR5 for anti-HIV research.以CCR5为靶点进行抗HIV研究。
Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):1881-7. doi: 10.1007/s10096-014-2173-0. Epub 2014 Jun 11.
5
Closing the door to human immunodeficiency virus.阻断人类免疫缺陷病毒。
Protein Cell. 2013 Feb;4(2):86-102. doi: 10.1007/s13238-012-2111-9. Epub 2013 Mar 12.
6
Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.七跨膜受体的变构调节：理论、实践及中枢神经系统药物发现的机遇
J Med Chem. 2012 Feb 23;55(4):1445-64. doi: 10.1021/jm201139r. Epub 2012 Jan 6.
7
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.Env 糖蛋白异质性是中和抗体和进入抑制剂抑制 HIV-1 感染中协同作用和增强协同作用的来源。
Virology. 2012 Jan 5;422(1):22-36. doi: 10.1016/j.virol.2011.09.019. Epub 2011 Oct 22.
8
Hendra and nipah infection: pathology, models and potential therapies.亨德拉病毒和尼帕病毒感染：病理学、模型及潜在疗法
Infect Disord Drug Targets. 2011 Jun;11(3):315-36. doi: 10.2174/187152611795768097.
9
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses.新型大环胺类化合物对野生型和多药耐药型病毒具有作为HIV进入抑制剂的活性。
Molecules. 2009 May 22;14(5):1927-37. doi: 10.3390/molecules14051927.
10
Chemokines as possible targets in modulation of the secondary damage after acute spinal cord injury: a review.趋化因子作为急性脊髓损伤后继发性损伤调节的潜在靶点：综述
Cell Mol Neurobiol. 2009 Sep;29(6-7):1025-35. doi: 10.1007/s10571-009-9392-4. Epub 2009 Apr 11.
本文引用的文献
1
Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.口服生物可利用的小分子CCR5拮抗剂TAK-220对人免疫缺陷病毒1型复制具有高效抑制作用。
Antimicrob Agents Chemother. 2005 Aug;49(8):3474-82. doi: 10.1128/AAC.49.8.3474-3482.2005.
2
Viral entry denied.病毒进入受阻。
N Engl J Med. 2004 Aug 19;351(8):743-4. doi: 10.1056/NEJMp048058.
3
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.成人HIV感染的治疗：美国国际艾滋病协会专家组2004年建议
JAMA. 2004 Jul 14;292(2):251-65. doi: 10.1001/jama.292.2.251.
4
Effects of HIV-1 entry inhibitors in combination.HIV-1进入抑制剂联合使用的效果
Curr Pharm Des. 2004;10(15):1861-5. doi: 10.2174/1381612043384501.
5
Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.恩夫韦肽与1-β-D-2,6-二氨基嘌呤二氧戊环在体外的良好相互作用。
Antimicrob Agents Chemother. 2003 Nov;47(11):3644-6. doi: 10.1128/AAC.47.11.3644-3646.2003.
6
Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.CCR5拮抗剂SCH-C（SCH 351125）与其他抗逆转录病毒药物在体外的抗人类免疫缺陷病毒相互作用。
Antimicrob Agents Chemother. 2002 May;46(5):1336-9. doi: 10.1128/AAC.46.5.1336-1339.2002.
7
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.HIV-1对一种小分子CCR5特异性进入抑制剂产生逃逸并不涉及使用CXCR4。
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):395-400. doi: 10.1073/pnas.012519099.
8
Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100.融合抑制剂T-20与CXCR4阻断剂AMD-3100之间存在强大的体外协同作用。
J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):99-102. doi: 10.1097/00042560-200010010-00001.
9
Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates.两种和三种蛋白酶抑制剂组合对药物敏感和耐药HIV-1分离株的相互作用。
J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):430-6. doi: 10.1097/00126334-199912150-00002.
10
In vivo antagonism with zidovudine plus stavudine combination therapy.齐多夫定与司他夫定联合治疗的体内拮抗作用。
J Infect Dis. 2000 Jul;182(1):321-5. doi: 10.1086/315683. Epub 2000 Jul 6.
Zotero 插件